신승현 (서울대학교 의과대학) | 한빛사논문 > 한빛사

한빛사논문

조회1,975

서울대학교 의과대학

CV File 87 kb

Nat. Commun., Published 05 October 2018, 9, Article number: 4113 | https://doi.org/10.1038/s41467-018-06606-2 Aberrant expression of CITED2 promotes prostate cancer metastasis by activating the nucleolin-AKT pathway

Seung-Hyun Shin^1,2,3, Ga Young Lee^1,2,3, Mingyu Lee^1,2,3, Jengmin Kang^1,2,3, Hyun-Woo Shin^1,2,3, Yang-Sook Chun^1,3 & Jong-Wan Park^1,2,3,*¹Department of Biomedical Science, BK21-plus Education Program, Seoul National University College of Medicine, Seoul, Korea. ²Department of Pharmacology, Seoul National University College of Medicine, Seoul, Korea. ³ Cancer Research Institute and Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, Seoul, Korea.

^*Correspondence to Jong-Wan Park

Abstract

Despite many efforts to develop hormone therapy and chemotherapy, no effective strategy to suppress prostate cancer metastasis has been established because the metastasis is not well understood. We here investigate a role of CBP/p300-interacting transactivator with E/D-rich carboxy-terminal domain-2 (CITED2) in prostate cancer metastasis. CITED2 is highly expressed in metastatic prostate cancer, and its expression is correlated with poor survival. The CITED2 gene is highly activated by ETS-related gene that is overexpressed due to chromosomal translocation. CITED2 acts as a molecular chaperone to guide PRMT5 and p300 to nucleolin, thereby activating nucleolin. Informatics and experimental data suggest that the CITED2?nucleolin axis is involved in prostate cancer metastasis. This axis stimulates cell migration through the epithelial?mesenchymal transition and promotes cancer metastasis in a xenograft mouse model. Our results suggest that CITED2 plays a metastasis-promoting role in prostate cancer and thus could be a target for preventing prostate cancer metastasis.

논문정보

형식Research article
게재일2018년 10월 (BRIC 등록일 2018-10-19)
연구진국내 연구진
분야

댓글 작성 로그인

CV 열람하기

연락처 보기